Clinical Staging of Ovarian Cancer

The Serum Level of Vascular Endothelial Growth Factor (VEGF) is Declined after Paclitaxel-Carboplatin Combined Chemotherapy Treatment on Epithelial Ovarian Cancer

Indonesian Journal of Obstetrics and Gynecology ◽

10.32771/inajog.v36i3.313 ◽

2016 ◽

Author(s):

Amelia Abdullah

Keyword(s):

Ovarian Cancer ◽

Cell Differentiation ◽

Serum Level ◽

Epithelial Ovarian Cancer ◽

Early Stage ◽

Clinical Staging ◽

Teaching Hospitals ◽

Advanced Stage ◽

Combined Chemotherapy ◽

Differentiated Cells

Objective: To assess the effect of Paclitaxel-Carboplatin combination on epithelial ovarian cancer by studying the changes in VEGF serum levels after receiving 3 series of chemotherapy. Methods: This was a cohort study conducted at several teaching hospitals in Obstetrics and Gynecology Department of the Faculty of Medicine, Hasanuddin University from April 2011 to March 2012. The subjects were patients with ovarian cancer who met the inclusion criteria and had undergone surgery. The clinical staging was determined with 2009 FIGO criteria. They went through histopathology examination to determine the histological type and cell differentiation of the lesion. They also went through combined chemotherapy of Paclitaxel and Carboplatin. The data were analyzed with paired t-test. Results: The study reveals that out of 30 cases of ovarian cancer who received a combination chemotherapy, most were < 45 years of age (53.33%), nulliparous (46.7%), serosum type (53.3%), with moderate differentiation (36.7%), and in advanced stage (73.3%). The VEGF serum level after 3 series of chemotherapy was lower than before (the average value: 294.67 vs 572.77 ng/ml). There was a significant change in VEGF serum level after receiving chemotherapy (p=0.000). The VEGF serum level of advanced-stage and early stage epithelial ovarian cancer after chemotherapy decreases significantly (p=0.000 and p=0.011). The advanced-stage cases showed more responses to chemotherapy than the early-stage did. There was a tendency that adenocarcinoma serosum type was more responsive to the therapy than mucinosum type (p=0.000 vs 0.003). Conclusion: There is no difference in VEGF serum level based on cell differentiation but there is a tendency that well and moderate differentiated cells have a greater change than the poor differentiated cells (p=0.003, p=0.003 vs p=0.019). [Indones J Obstet Gynecol 2012; 36-3: 135-9] Keywords: carboplatin, epithelial ovarian cancer, paclitaxel, VEGF

Download Full-text

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer

Open Medicine ◽

10.1515/med-2016-0024 ◽

2016 ◽

Vol 11 (1) ◽

pp. 125-132 ◽

Cited By ~ 7

Author(s):

Li-e Zheng ◽

Jun-ying Qu ◽

Fei He

Keyword(s):

Ovarian Cancer ◽

Ovarian Tumors ◽

Clinical Staging ◽

Ca 125 ◽

Cancer Antigen 125 ◽

Healthy Women ◽

Cancer Group ◽

Clinical Biomarker ◽

Benign Ovarian Tumors ◽

The Relationship

AbstractObjectiveTo evaluate the value of individual and combined measurement of human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125) in the diagnosis of ovarian cancer.MethodsA clinical case-control study was performed in which the levels of serum HE4 and CA-125 of subjects with malignant, borderline, benign ovarian tumors and healthy women were measured before surgery. An immunohistochemistry method was used to measure the expression of HE4 in different tissues. Statistical analysis was performed to determine the relationship between the level of HE4 and the pathologic type as well as the stage of the ovarian tumors.ResultsThe level of HE4 in the serum was significantly elevated in the malignant ovarian cancer group compared with other groups. Women with benign ovarian tumors and non-neoplastic lesions, and healthy women were designated as references. When the level of HE4 in the serum was 58.66 pmol/L, the sensitivity and specificity of HE4 in diagnosing malignant ovarian tumors was 82.35% and 96.03%, respectively. The level of HE4 was negatively correlated with the differentiation extent of the tumors whereas positively correlated to the clinical staging. In the groups of malignant and borderline tumors, the levels of HE4 were higher than the other groups. The expression of HE4 was significant higher in the serous types of ovarian tumors than that of the mucous types (P<0.05). The level of HE4 in the serum and tissues were positively correlated with each other.ConclusionHE4 can be used as a novel clinical biomarker for predicting malignant ovarian tumors and its expression was closely related with the clinical pathological features of malignant ovarian tumors.

Download Full-text

Knockdown of ZNF280A inhibits the development and progression of ovarian cancer

10.21203/rs.3.rs-27424/v2 ◽

2020 ◽

Author(s):

Dawei Zhu ◽

Xing Gu ◽

Li Li ◽

Xuebing Chen ◽

Jie Huang

Keyword(s):

Ovarian Cancer ◽

Animal Experiments ◽

Clinical Staging ◽

Potential Therapeutic Target ◽

Migration Ability ◽

Normal Tissues ◽

And Migration ◽

Proliferation And Migration

Abstract Background: Ovarian cancer (OC) is one of the leading causes of death from gynecological malignancies worldwide. Abnormal expression of zinc finger proteins has been extensively reported to be involved in malignant progression in a variety of cancers. However, clinical significance and biological roles of ZNF280A in the field of OC are poorly known. Methods: In this study, we demonstrated that ZNF280A was highly expressed in OC tissues compared with adjacent normal tissues. Further, ZNF280A was significantly associated with clinical staging, infiltration, lymphatic metastasis, metastasis, and tumor recurrence of OC patients. Additionally, data of in vitro experiments indicated that knockdown of ZNF280A by its shRNA dramatically reduces the proliferation and migration ability of OC cells, while enhancing the cell apoptosis. Results: It was also verified by animal experiments that ZNF280A silencing would affect the growth of OC in vivo. Our study investigated the involvement of ZNF280A in the prognosis, progression and metastasis of OC. Conclusions: Therefore, our study identified ZNF280A as an optional prognostic factor in OC patients and can be used as a potential therapeutic target for the treatment of OC.

Download Full-text

Identification of Core Predication-Related Candidate Genes in Ovarian Cancer Based on Integrated Bioinformatics and Experienment

10.21203/rs.3.rs-757589/v1 ◽

2021 ◽

Author(s):

Jiaqing Bi ◽

Qian Qin ◽

Huihan Ma ◽

Meijie Ma ◽

Qinmei Feng

Keyword(s):

Ovarian Cancer ◽

Survival Analysis ◽

Early Diagnosis ◽

Correlation Analysis ◽

Candidate Genes ◽

Functional Enrichment ◽

Biological Behavior ◽

Clinical Staging ◽

Ppi Network ◽

Joint Monitoring

Abstract Background: Ovarian cancer is one of the deadliest and most common gynecological malignancies. This study aims to use comprehensive bioinformatics analysis to try to identify the core candidate genes related to the prediction of ovarian cancer for the early diagnosis and prognosis of ovarian cancer. Methods: Obtain expression profiles from Gene Expression Omnibus database, identify differentially expressed genes (DEG) with p<0.05 and (logFC)>1.5, perform functional enrichment, protein-protein interaction (PPI) network construction, functional module analysis, and survival analysis And correlation analysis to obtain the target gene, through immunohistochemical staining, clinicopathological feature analysis to verify the expression and clinical significance of TTK.Results: 1. Identified 135 genes with the same expression. 33 up-regulated DEG were mainly enriched in mitotic spindle assembly checkpoints, chromosome segregation regulation, etc.; 102 down-regulated DEG was mainly enriched in neurotransmitter level regulation, protein serine/threonine Regulation of acid kinase activity, etc. Then the PPI network was constructed to screen 20 hub genes and perform survival analysis and expression correlation analysis. At the same time, the modules that met the requirements were screened and the genes were analyzed by pathway enrichment. It was found that TTK was highly expressed in ovarian cancer and led to a poor prognosis.2. Distant metastasis, lymph node metastasis, clinical staging (stage III-IV), and poor differentiation are independent risk factors for high TTK expression (P<0.05).3. TTK, CA125, HE4 three biological indicators show excellent diagnostic value in joint monitoring of ovarian cancer.Conclusions: TTK plays a vital role in the tumorigenesis, aggressiveness and malignant biological behavior of EOC, and can be used as a potential biomarker and potential therapeutic target for early diagnosis and predictive evaluation of EOC.

Download Full-text

Knockdown of ZNF280A inhibits the development and progression of ovarian cancer

10.21203/rs.3.rs-27424/v1 ◽

2020 ◽

Author(s):

Dawei Zhu ◽

Xing Gu ◽

Li Li ◽

Xuebing Chen ◽

Jie Huang

Keyword(s):

Ovarian Cancer ◽

Animal Experiments ◽

Clinical Staging ◽

Potential Therapeutic Target ◽

Migration Ability ◽

Normal Tissues ◽

And Migration ◽

Proliferation And Migration

Abstract Background Ovarian cancer (OC) is one of the leading causes of death from gynecological malignancies worldwide. Abnormal expression of zinc finger proteins has been extensively reported to be involved in malignant progression in a variety of cancers. However, clinical significance and biological roles of ZNF280A in the field of OC are poorly known. Methods In this study, we demonstrated that ZNF280A was highly expressed in OC tissues compared with adjacent normal tissues. Further, ZNF280A was positively associated with clinical staging, infiltration, lymphatic metastasis, metastasis, and tumor recurrence of OC patients. Additionally, data of in vitro experiments indicated that knockdown of ZNF280A by its shRNA dramatically reduced the proliferation and migration ability of OC cells, while enhancing the cell apoptosis. Results It was also verified by animal experiments that ZNF280A silencing would affect the growth of OC in vivo. Our study investigated the involvement of ZNF280A in the prognosis, progression and metastasis of OC. Conclusions Therefore, ZNF280A was identified as an optional prognostic factor in OC patients and can be used as a potential therapeutic target for the treatment of OC.

Download Full-text

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer

Iranian Journal of Public Health ◽

10.18502/ijph.v50i6.6418 ◽

2021 ◽

Author(s):

Qiuhua Wan ◽

Yiping Liu ◽

Bo Lv ◽

Xiaofang Chen

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Normal Control ◽

Normal Control Group ◽

Clinical Staging ◽

Control Group ◽

Cancer Group ◽

Serum Ca125 ◽

Primary Epithelial Ovarian Cancer ◽

Recurrence Group

Background: This study was designed to explore the levels of serum moleculartumor markers carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), and carcinoembryonic antigen (CEA) in patients with primary epithelial ovarian cancer, and their correlation with the progression of the cancer. Methods: A total of 222 people were enrolled in this study admitted to Jining Maternal and Child Health and Family Planning Service Center from January 2016 to December 2017. There were 122 patients with primary epithelial ovarian cancer (ovarian cancer group), 50 patients with benign ovarian diseases (benign control group), and 50 healthy individuals (normal control group). The levels of serum CA125, CEA, and HE4 were detected by the electrochemical luminescence method and ELISA. Results: The levels of serum CA125, HE4, and CEA in the ovarian cancer group were significantly higher than those in patients with the benign control group and the normal control group (P<0.01). The levels of serum CA125, HE4, and CEA in the high clinical staging group (stage III and stage II), low differentiation group, comorbid ascites group, metastasis group, and recurrence group were significantly higher than those in the low clinical staging group (stage I and stage II), high + moderate differentiation group, non-ascites group, non-metastasis group, and non-recurrence group, respectively (all P<0.05), and the levels of serum CA125, HE4, and CEA decreased significantly after treatment (P<0.01). Conclusion: The levels of serum CA125, HE4, and CEA are closely related to the development and progression of epithelial ovarian cancer, and combined detection of CA125, HE4 and CEA is of great significance for early diagnosis, disease development monitoring, and prognosis evaluation of epithelial ovarian cancer.

Download Full-text

ADNEX Model-Based Diagnosis of Ovarian Cancer Using MRI Images

Contrast Media & Molecular Imaging ◽

10.1155/2021/2146578 ◽

2021 ◽

Vol 2021 ◽

pp. 1-8

Author(s):

Bin Liu ◽

Jianmei Liao ◽

Wenli Gu ◽

Junyan Wang ◽

Guozhang Li ◽

...

Keyword(s):

Ovarian Cancer ◽

Reference Value ◽

Cancer Staging ◽

Diagnostic Value ◽

Diagnostic Methods ◽

Clinical Staging ◽

Significant Difference ◽

Mri Diagnosis ◽

Magnetic Resonance Imaging Mri ◽

Sensitivity Specificity

This exploration aims to investigate the important role of magnetic resonance imaging (MRI) in the diagnosis of ovarian cancer under the ADNEX. From March 2017 to December 2019, 84 patients with ovarian cancer confirmed by pathological operation were selected as the research objects. The consistency of ADNEX, MRI, and ADNEX ∗ MRI in the diagnosis and staging of ovarian cancer was calculated separately. SPSS 26.0 statistical software was used to compare the accuracy, sensitivity, specificity, and diagnostic value of the two diagnostic methods. The results show that the accuracy and sensitivity of ADNEX are 78.6% and 93.2%, respectively. The accuracy and sensitivity of MRI are 81.2% and 89.4%, respectively. There is no significant difference between the two methods ( p < 0.05 ). The overall consistency rates of ADNEX ∗ MRI, MRI diagnosis, and ADNEX for ovarian cancer staging are 94.2%, 74%, and 65.4%, respectively. There was a significant difference ( p < 0.05 ). ADNEX ∗ MRI and MRI diagnosis were compared with each stage of ADNEX. There is a significant difference between the second and fourth stages ( p < 0.05 ), and there is also a significant difference in the fourth stage ( p < 0.017 ). It is concluded that MRI diagnosis of ovarian cancer based on ADNEX is superior to ADNEX and MRI examination alone, which provides a certain reference value for clinical staging of ovarian cancer.

Download Full-text